Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer Boehringer Ingelheim, the second in the past two months. Another jury in the ...

“Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time. We are proud to be able to offer Lyumjev compatibility with our t:slim X2 pump as part of ...

(Reuters) – The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer ...

Boehringer Ingelheim, GSK, Pfizer and Sanofi all sold brand name Zantac at various times since it was approved in 1983, and have been named in tens of thousands of lawsuits over the alleged cancer ...

(Reuters) – The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether ...

GSK affirmed that it would continue to defend itself against ongoing litigation concerning Zantac. At 1402 BST, shares in GSK were down 0.43% at 1,602.5p. Reporting by Josh White for Sharecast.com.

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but won’t be the last. A juror’s note—"I must leave. This has not been resolved" ...